Health Care & Life Sciences » Biotechnology | Chiome Bioscience Inc.

Chiome Bioscience Inc. | Balance Sheet

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
989
5,576
4,100
4,553
4,027
2,329
Total Accounts Receivable
63
80
102
79
76
77
Inventories
22
55
42
35
35
45
Other Current Assets
11
25
29
14
59
159
Total Current Assets
1,085
5,737
4,274
4,682
4,197
2,610
Net Property, Plant & Equipment
117
399
436
35
23
16
Total Investments and Advances
85
73
186
72
197
150
Intangible Assets
9
49
23
-
-
-
Other Assets
-
1
-
1
2
55
Total Assets
1,297
6,257
4,919
4,789
4,419
2,831
ST Debt & Current Portion LT Debt
111
21
46
50
4
Accounts Payable
22
44
30
23
28
Income Tax Payable
5
9
12
21
29
Other Current Liabilities
100
221
150
76
100
Total Current Liabilities
238
295
238
169
161
Long-Term Debt
21
-
54
4
-
Provision for Risks & Charges
-
48
50
51
41
Deferred Taxes
-
15
13
-
-
Other Liabilities
-
60
-
-
-
Total Liabilities
259
418
355
224
202
Common Equity (Total)
1,038
5,828
4,564
4,565
4,218
Total Shareholders' Equity
1,038
5,828
4,564
4,565
4,218
Total Equity
1,038
5,839
4,564
4,565
4,218
Liabilities & Shareholders' Equity
1,297
6,257
4,919
4,789
4,419
Accumulated Minority Interest
-
12
-
-
-

About Chiome Bioscience

View Profile
Address
Sumitomo Fudosan Nishi-Shinjuku Bldg
Tokyo Tokyo 151
Japan
Employees -
Website http://www.chiome.co.jp
Updated 07/08/2019
Chiome Bioscience, Inc. engages in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) System. Its operations are carried out through Innovative Drug and Innovative Drug Support business segments. The Innovative Drug segment manufactures specific antibodies based on new antigen mechanisms and licenses these out to pharmaceutical industries.